Skip to main content
Premium Trial:

Request an Annual Quote

Serenex Signs Chemoproteomics Deal with Lilly

NEW YORK, Aug. 5 (GenomeWeb News) - Serenex said today that Eli Lilly would use its chemoproteomics technology in select drug discovery programs.


Lilly will have access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against thousands of protein targets simultaneously.


According to Serenex, the companies will evaluate how these technologies impact the lead identification process.


Financial terms of the agreement were not provided.


This agreement follows similar ones announced in May with GlaxoSmithKline, and in September 2002 with Chiron.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.